CLINICAL TRIALS PROFILE FOR PATANOL
✉ Email this page to a colleague
All Clinical Trials for Patanol
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00609128 ↗ | Effect of Olopatadine on Allergic Tear Mediators | Completed | National Eye Institute (NEI) | N/A | 2000-09-01 | The purpose of the research is to determine which inflammatory substances are involved in causing allergic symptoms in the eye. Allergic conjunctivitis is a common problem with symptoms of temporary redness, itching, tearing, and swelling of the eyes. Substances released by cells in the affected tissues cause allergic reactions in the eye and elsewhere in the body. |
| NCT00609128 ↗ | Effect of Olopatadine on Allergic Tear Mediators | Completed | University of Wisconsin, Madison | N/A | 2000-09-01 | The purpose of the research is to determine which inflammatory substances are involved in causing allergic symptoms in the eye. Allergic conjunctivitis is a common problem with symptoms of temporary redness, itching, tearing, and swelling of the eyes. Substances released by cells in the affected tissues cause allergic reactions in the eye and elsewhere in the body. |
| NCT01119287 ↗ | Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis | Completed | Alcon Research | Phase 4 | 2010-03-01 | The purpose of this study was to evaluate the efficacy of Maxidex and Patanol compared to placebo in patients with allergic conjunctivitis when exposed to controlled allergen levels in an Environmental Exposure Chamber (EEC). |
| NCT01435460 ↗ | Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC) | Completed | Bausch & Lomb Incorporated | Phase 3 | 2010-08-01 | This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%) versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs and symptoms of Seasonal Allergic Conjunctivitis (SAC). |
| NCT02478398 ↗ | Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2015-07-20 | The purpose of this study is to assess the efficacy and safety of short ragweed pollen allergen extract (MK-3641, SCH 039641, RAGWITEK™) sublingual immunotherapy tablets in children aged 5 to 17 years with ragweed-induced allergic rhinitis/rhinoconjunctivitis with or without asthma. The primary hypothesis of this study is that administration of short ragweed pollen allergen extract sublingual immunotherapy tablets to children 5 to 17 years of age, compared with placebo, will result in a significant reduction in the combination of rhinoconjunctivitis symptoms and medication use over the peak ragweed season (RS). |
| NCT03186755 ↗ | Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis | Recruiting | Université de Montréal | Phase 4 | 2017-06-11 | This study compares the efficacy of Hylo-Dual (Hyaluronic acid 0.05% & Ectoine 2.0%) and Olopatadine (Olopatadine hydrochloride ophthalmic solution 0.1%) in the control of seasonal allergic conjunctivitis in the pediatric population. Half of participants will receive Hylo-Dual, while the other half will receive Olopatadine treatment for 2 months. |
| NCT03186755 ↗ | Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis | Recruiting | Michael Marchand, MD | Phase 4 | 2017-06-11 | This study compares the efficacy of Hylo-Dual (Hyaluronic acid 0.05% & Ectoine 2.0%) and Olopatadine (Olopatadine hydrochloride ophthalmic solution 0.1%) in the control of seasonal allergic conjunctivitis in the pediatric population. Half of participants will receive Hylo-Dual, while the other half will receive Olopatadine treatment for 2 months. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Patanol
Condition Name
Clinical Trial Locations for Patanol
Trials by Country
Clinical Trial Progress for Patanol
Clinical Trial Phase
Clinical Trial Sponsors for Patanol
Sponsor Name
